Abstract
Although genistein has been shown to inhibit tumorigenesis in a variety of human cancers including pancreatic cancer (PC), the exact molecular mechanism of its anti-cancer effects has not yet been fully elucidated. Recently, microRNAs (miRNAs) have been reported to regulate multiple aspects of tumor development and progression, indicating that targeting miRNAs could be a novel strategy to treat human cancers. In the current study, we investigated whether a natural compound genistein could down-regulate onco-miR-223, resulting in the inhibition of cell growth and invasion, and induction of apoptosis in PC cells. We found that genistein treatment significantly inhibited miR-223 expression and up-regulated Fbw7, one of the targets of miR-223. Moreover, down-regulation of miR-223 inhibited cell growth and induced apoptosis in PC cells. These findings suggest that genistein exerts its anti-tumor activity partly through downregulation of miR-223 in PC cells.
Keywords: miR-223, Fbw7, apoptosis, cell growth, genistein, pancreatic cancer.
Current Drug Targets
Title:Genistein Down-Regulates miR-223 Expression in Pancreatic Cancer Cells
Volume: 14 Issue: 10
Author(s): Jia Ma, Long Cheng, Hao Liu, Jing Zhang, Ying Shi, Fanpeng Zeng, Lucio Miele, Fazlul H Sarkar, Jun Xia and Zhiwei Wang
Affiliation:
Keywords: miR-223, Fbw7, apoptosis, cell growth, genistein, pancreatic cancer.
Abstract: Although genistein has been shown to inhibit tumorigenesis in a variety of human cancers including pancreatic cancer (PC), the exact molecular mechanism of its anti-cancer effects has not yet been fully elucidated. Recently, microRNAs (miRNAs) have been reported to regulate multiple aspects of tumor development and progression, indicating that targeting miRNAs could be a novel strategy to treat human cancers. In the current study, we investigated whether a natural compound genistein could down-regulate onco-miR-223, resulting in the inhibition of cell growth and invasion, and induction of apoptosis in PC cells. We found that genistein treatment significantly inhibited miR-223 expression and up-regulated Fbw7, one of the targets of miR-223. Moreover, down-regulation of miR-223 inhibited cell growth and induced apoptosis in PC cells. These findings suggest that genistein exerts its anti-tumor activity partly through downregulation of miR-223 in PC cells.
Export Options
About this article
Cite this article as:
Ma Jia, Cheng Long, Liu Hao, Zhang Jing, Shi Ying, Zeng Fanpeng, Miele Lucio, Sarkar H Fazlul, Xia Jun and Wang Zhiwei, Genistein Down-Regulates miR-223 Expression in Pancreatic Cancer Cells, Current Drug Targets 2013; 14 (10) . https://dx.doi.org/10.2174/13894501113149990187
DOI https://dx.doi.org/10.2174/13894501113149990187 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic
Current Medicinal Chemistry Therapeutic Potential of Natural Compounds in Lung Cancer
Current Medicinal Chemistry Recent Progress of Src Family Kinase Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry The Posttranslational Phase of Gene Expression: New Possibilities in Molecular Diagnosis
Current Molecular Medicine Baseline CD4/CD8 T-Cell Ratio Predicts Prompt Immune Restoration Upon cART Initiation
Current HIV Research microRNAs, Gap Junctional Intercellular Communication and Mesenchymal Stem Cells in Breast Cancer Metastasis
Current Cancer Therapy Reviews Alternative Splicing: A Promising Target for Pharmaceutical Inhibition of Pathological Angiogenesis?
Current Pharmaceutical Design Protein Phosphatase 1 and Its Complexes in Carcinogenesis
Current Cancer Drug Targets Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer
Current Drug Targets Cancer Therapy: Targeting Cell Cycle Regulators
Anti-Cancer Agents in Medicinal Chemistry Cancer Proteomics: New Horizons and Insights into Therapeutic Applications
Current Proteomics Caveolin-1: A Promising Therapeutic Target for Diverse Diseases
Current Molecular Pharmacology Current Advances in the Biological Activity of Polysaccharides in Dendrobium with Intriguing Therapeutic Potential
Current Medicinal Chemistry Gap Junctions as Targets for Cancer Chemoprevention and Chemotherapy
Current Drug Targets Mechanisms of Anti-retroviral Drug Resistance: Implications for Novel Drug Discovery and Development
Infectious Disorders - Drug Targets Application of Charge Transfer Reactions for the Quantitative Spectrophotometric Determination of Cyclophosphamide in Pure and Pharmaceutical Formulation
Current Pharmaceutical Analysis Potential Gene Therapy Strategies for Cancer Stem Cells
Current Gene Therapy Heterocyclic Scaffolds: Centrality in Anticancer Drug Development
Current Drug Targets Anticancer Activity of Lectins from <i>Bauhinia purpurea</i> and <i>Wisteria floribunda</i> on Breast Cancer MCF-7 Cell Lines
Protein & Peptide Letters Clinical Trials of Cancer Therapies Targeting Prostate-Specific Membrane Antigen
Reviews on Recent Clinical Trials